access

ANYTIME. ANYWHERE. ANY FOOD.1

Offer your pediatric patients treatment flexibility with the only oral TPO-RA that has no treatment injections, liver toxicity, or dietary restrictions—available in both tablet and oral granules (coming soon).1-3

TPO-RA characteristics to consider*

Scroll left and right to view the full chart.

 
Product characteristicsAvatrombopag1Eltrombopag2‡Romiplostim3§
Oral administration

Oral administration

Bioavailability not impacted by food type

Bioavailability not impacted by food type 

Single dosage strength per formulation†

No dose restrictions

No dose restrictions based on population ancestry demographics

Additional suspension formulation

Additional formulation for kids (≥1 to <6)

 

‡

 

Doptelet and Doptelet Sprinkle don’t require extra eye exams or liver function monitoring.1,4-6

Doptelet tablets and Doptelet Sprinkle are not substitutable on a mg-to-mg basis.1

Kid-friendly dosing

Single dosing strength per formulation enables greater dosing flexibility for patients to help meet treatment goals1,7†

Oral tablet

Oral granules

Increase dosage if platelet count is <50x109/L

Reduce dosage if platelet count is >200 and ≤400x109/L

Dose level
Oral tablet

ages ≥6 years

6
40 mg 1x per day
5
40 mg 3x per week, 20 mg on remaining days
Starting dose
4
20 mg 1x per day
3
20 mg 3x per week
2
20 mg 2x per week OR 40 mg 1x per week
1
20 mg 1x per week
Oral granules
dosing

Coming soon

Sobi is working quickly to make Doptelet Sprinkle available. Sign up to be notified as soon as it’s available.
 

  • Select the recommended product (Doptelet tablets or Doptelet Sprinkle oral granules) based on the indication and patient’s age1
  • Doptelet tablets and Doptelet Sprinkle are not substitutable on a mg-to-mg basis1

Doptelet tablets: Start patients taking moderate or strong dual inhibitors of CYP2C9 and CYP3A4 with 20 mg 3 times a week; start patients taking moderate or strong dual inducers of CYP2C9 and CYP3A4 with 40 mg once daily.1

Doptelet Sprinkle: Start patients taking moderate or strong dual inhibitors of CYP2C9 and CYP3A4 with 10 mg (contents of 1 capsule) 3 times a week; start patients taking moderate or strong dual inducers of CYP2C9 and CYP3A4 with 20 mg (contents of 2 capsules) once daily.1

Please see full Prescribing Information for additional information on dose adjustments.

Titration Calculator

Want more information on dosing & titration? Answer these 3 questions:

1

I’m looking for dosing recommendations for:

Starting patients on Doptelet Titrating for a patient already taking Doptelet
2

Is your patient taking moderate or strong dual inducers or moderate or strong dual inhibitors of CYP2C9 and CYP3A4?

Yes No
2

What is your patient’s platelet count?
Platelet count (x109/L)

Below goal: <50 after
2 weeks of treatment At goal: 50-200 Above goal: 201-400 Above goal: >400
3

My patient is taking:

Moderate or strong dual inhibitors of CYP2C9 and CYP3A4 Moderate or strong dual inducers of CYP2C9 and CYP3A4
3

My patient is currently taking Doptelet at this dosage strength:

LEVEL 1
20 mg
once a week
LEVEL 2
20 mg
twice a week
OR
40 mg
once a week
LEVEL 3
20 mg
3 times a week
LEVEL 4
20 mg
once a day
LEVEL 5
40 mg
3 times a week
AND
20 mg on
4 remaining days
LEVEL 6
40 mg
once a day
Result

Recommended starting dose:
20 mg once daily.

New Calculation

*Dosing comparisons do not imply efficacy or safety.
†After initiating therapy with Doptelet or Doptelet Sprinkle, assess platelet counts weekly until a stable platelet count of ≥50x109/L has been achieved, and then obtain platelet counts weekly for at least 4 weeks following discontinuation of treatment. Doptelet and Doptelet Sprinkle are not used to make platelet counts normal.1
‡Eltrombopag must be taken at least 2 hours before or 4 hours after other medications, calcium-rich foods, or supplements containing polyvalent cations. Some versions of eltrombopag do offer an additional suspension formulation.2
§Romiplostim requires office visits for treatment injections.3

TPO-RA=thrombopoietin receptor agonist.

Doptelet Platelet Characters Having a Picnic

Help your patients access treatment

Find the support and resources you need to get your patients started on Doptelet or Doptelet Sprinkle.

View Access

Doptelet Platelet Photographer Character

Connect with an expert

Get guidance on starting treatment, managing access, and supporting your patients taking Doptelet and Doptelet Sprinkle.

REQUEST SUPPORT

  1. DOPTELET (avatrombopag) [prescribing information]. Morrisville, NC: AkaRx, Inc; 2025.
  2. Promacta (eltrombopag) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2023.
  3. Nplate (romiplostim) [prescribing information]. Thousand Oaks, CA: Amgen; 2025.
  4. Data on file. Clinical study report for AVA-PED-301. 2025: Sobi, Inc.
  5. Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479-490.
  6. Bussel J, Allen LF, Aggarwal K, Vredenburg M, Tian W, Liebman W. Lack of clinically significant hepatotoxicity in patients with chronic immune thrombocytopenia treated with the novel, oral thrombopoietin receptor antagonist avatrombopag: pooled safety analysis of four clinical studies. Poster presented at: ISTH Conference 2019. July 6-10, 2019; Melbourne, Australia. Abstract PB0418.
  7. Kapoor DU, Garg R, Gaur M, et al. Pediatric drug delivery challenges: enhancing compliance through age-appropriate formulations and safety measures. J Drug Deliv Sci Technol. 2024;96:105720.